Femasys Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Atlanta, april 18, 2024 (globe newswire) -- femasys inc. (nasdaq: femy), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, today announces its ceo and founder kathy lee-sepsick has met with several members of congress to discuss the current women's healthcare landscape. further, lee-sepsick is raising awareness of femasys and the status of its reproductive products in light of the recently announced women's health initiative from the white house. in mid-march president biden released an executive order, which calls for a $200m investment in research for women's health and a coordinated approach from more than 20 federal government agencies in addition to the $100m investment announced in november 2023.

Following fda clearance of femaseed®, company secures capital to support commercial initiatives; cash expected to fund operations into 2h 2025 following fda clearance of femaseed®, company secures capital to support commercial initiatives; cash expected to fund operations into 2h 2025

-- ceo kathy lee-sepsick and chief medical officer james liu to join jones trading analyst catherine novack in a conversation on current treatment options in infertility including femaseed® at 1pm et -- -- ceo kathy lee-sepsick and chief medical officer james liu to join jones trading analyst catherine novack in a conversation on current treatment options in infertility including femaseed® at 1pm et --

-- in the severe male factor cohort, findings show 24% of women became pregnant after femaseed -- -- femaseed pregnancy rate by cycle was more than double historic intrauterine insemination (iui) rate --

-- paving the way forward for the broader commercial availability of femaseed, an accessible, safe, and cost effective alternative to ivf -- -- ongoing uncertainty following recent alabama supreme court ruling creates continued anticipation with top-line pivotal data expected to be announced during q1 2024 --

Penny stocks can be a treasure trove of investment opportunities, and the list of Most Active Penny Stocks is a good place to start looking. The downside is that many penny stocks are active for no good fundamental reason and have only volatility to offer investors.

Underlying prices exhibited a notable cooling trend, providing the Federal Reserve shows evidence of softer inflation. While Americans did indeed spend more on costly gasoline and services during the month, this moderation in other price components underscores the nature of inflationary pressures.

Femasys (NASDAQ: FEMY ) stock is rocketing higher on Tuesday following approval from the Food and Drug Administration (FDA) for FemaSeed. FemaSeed is an infertility treatment that delivers sperm directly into a woman's fallopian tube.

Shares of biomedical firm Femasys (NASDAQ: FEMY ) more than doubled on Thursday. This followed an important intellectual property (IP) protection announcement.

After losing some value lately, a hammer chart pattern has been formed for Femasys Inc. (FEMY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace Hotel in New York, NY.

ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, “Early-Stage Medtech and Going Public.” The MedTech Conference, an annual event powered by AdvaMed, convenes the world's leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys, having previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic, Inc., both medical technology companies focused on women's healthcare...